On Monday US drug maker Eli Lilly said that it will issue voluntary licence to Hyderbad based NSE 0.70 % , ending the legal battle that was brimming over compulsory license for the drug in less than a month. "Natco will be collaborating with Lilly to further accelerate and expand the availability of baricitinib in India during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling COVID-19